MHRA Drug Safety Update for February 2021
- Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury
- Pregabalin (Lyrica): reports of severe respiratory depression
- Alkindi (hydrocortisone granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules
- Medicines in pregnancy and breastfeeding: new initiative for consistent guidance; report on optimising data for medicines used during pregnancy
- COVID-19 vaccines and medicines: updates for February 2021
You can sign up to receive these alerts directly from the MHRA at: MHRA email alerts
Published 26/03/21. Medicines Update blogs are correct at the time of publication